Find a lawyerOur capabilitiesYour careerSearch
Locations
Our capabilities
News

Select language:

Locations
Our capabilities
News

Select language:

hamburger menu showcase image
  1. Our thinking
  2. News
  3. News Search
  4. Freshfields advises HUTCHMED on the divestment of its 45% equity in Shanghai Hutchison Pharmaceuticals Limited
1MIN
Freshfields advises HUTCHMED on the divestment of its 45% equity in Shanghai Hutchison Pharmaceuticals Limited
Jan 3 2025

Global law firm Freshfields is advising HUTCHMED (China) Limited (‘HUTCHMED’) on the divestment of its 45% equity interest in Shanghai Hutchison Pharmaceuticals Limited for approximately US$608 million (RMB4,478 million) in cash, to GP Health Service Capital Co., Ltd and Shanghai Pharmaceuticals Holding Co., Ltd. The transaction constitutes a major transaction of HUTCHMED under the Hong Kong Listing Rules and is subject to various conditions, including approval of shareholders of HUTCHMED at an extraordinary general meeting. Additional information is available here.

HUTCHMED is a biopharmaceutical company listed on the Hong Kong Stock Exchange (stock code: 13), the AIM market of the London Stock Exchange (stock code: HCM) and in the form of American depositary shares on the NASDAQ Global Select Market (ticker symbol: HCM).

The Freshfields team advising as the Hong Kong counsel on the transaction was led by partner Grace Huang with support from counsel Cindy Kwong, and associate Kristy Wong.

Team
Hong Kong
Grace HuangPartner
Hong Kong
Cindy KwongCounsel
Hong Kong
Kristy WongAssociate
FIND US IN
All locations
NAVIGATE TO
About usYour careerOur thinkingOur capabilitiesNews
CONNECT
Find a lawyerAlumniContact us
NEED HELP
Fraud and scamsComplaintsTerms and conditions
LEGAL
AccessibilityCookiesLegal noticesTransparency in supply chains statementResponsible procurementPrivacy

© 2025 Freshfields. Attorney Advertising: prior results do not guarantee a similar outcome

Select language: